Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02979977
Recruitment Status : Recruiting
First Posted : December 2, 2016
Last Update Posted : May 6, 2021
Sponsor:
Collaborators:
National Comprehensive Cancer Network
Boehringer Ingelheim
Information provided by (Responsible Party):
Yale University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : January 2022